{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"175-489-104-173-217","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"175-489-104-173-217","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11849,"type":"PATENT","title":"University of Liege Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6891,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8461,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Liege. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1416
Search Applicants and Owners separately:univ* AND Liege. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1416
exposing the DNA to a methylation-sensitive mapping restriction enzyme (MMRE) to generate a plurality of first fragments;\n
conjugating to one terminus or to both termini of each of the first fragments a binding moiety, the binding moiety comprising a first member of an affinity pair, the conjugating resulting in a plurality of second fragments;\n
exposing the plurality of second fragments to a fragmenting restriction enzyme (FRE) to generate a plurality of third fragments, each third fragment comprising at one terminus the first member of the affinity pair and at the other terminus the 5′ cut sequence of the FRE or the 3′ cut sequence of the FRE;\n
contacting the plurality of third fragments with an insoluble substrate having bound thereto a plurality of second members of the affinity pair, said contacting resulting in a plurality of bound third fragments, each bound third fragment being a third fragment bound via the first and second members of the affinity pair to the insoluble substrate;\n
conjugating to free termini of the bound third fragments a releasing moiety, the releasing moiety comprising a releasing restriction enzyme (RRE) recognition sequence and, 3′ of the recognition sequence of the RRE, either the 5′ cut sequence of the FRE or the 3′ cut sequence of the FRE, the conjugating resulting in a plurality of bound fourth fragments, each bound fourth fragment (i) comprising at one terminus the recognition sequence of the RRE and (ii) being bound via the first member of the affinity pair at the other terminus and the second member of the affinity pair to the insoluble substrate; and\n
exposing the bound fourth fragments to the RRE, the exposing resulting in the release from the insoluble substrate of a MSDK library, the library comprising a plurality of fifth fragments, each fifth fragment comprising the releasing moiety and a MSDK tag, the tag consisting of a plurality of base pairs of the genomic DNA."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the MMRE is AscI."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the FRE is NlaIII."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the RRE is MmeI."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the binding moiety further comprises a 5′ or 3′ cut sequence of the MMRE."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the binding moiety further comprises, between the 5′ or 3′ recognition sequence of the MMRE and the first member of an affinity pair, a linker nucleic acid sequence comprising a plurality of base pairs."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the releasing moiety further comprises, 5′ of the RRE recognition sequence, an extender nucleic acid sequence comprising a plurality of base pairs."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A method of analyzing a MSDK library, the method comprising;\n
providing a MSDK library made by the method of claim 1;\n
identifying the nucleotide sequences of one tag, a plurality of tags, or all of the tags."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, wherein identifying the nucleotide sequences of a plurality of tags comprises:\n
making a plurality of ditags, each ditag comprising two fifth fragments ligated together;\n
forming a concatamer comprising a plurality of ditags or ditag fragments, wherein each ditag fragment comprises two MSDK tags;\n
determining the nucleotide sequence of the concatamer; and\n
deducing, from the nucleotide sequence of the concatamer, the nucleotide sequences of one or more of the MSDK tags that the concatamer comprises."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the ditag fragments are made by exposing ditags to the FRE."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, further comprising, after making a plurality of ditags and prior to forming the concatamers, increasing the number of ditags by PCR."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8, further comprising determining the relative frequency of some or all of the tags."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method of analyzing a MSDK library, the method comprising:\n
providing a MSDK library made by the method of claim 1; and\n
identifying a chromosomal site corresponding to the sequence of a tag selected from the library."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, further comprising determining a chromosomal location, in the genome of the test cell, of an unmethylated full recognition sequence of the MMRE closest to the identified chromosomal site."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the identification of the chromosomal site and the determination of the chromosomal location is performed by a process comprising comparing the nucleotide sequence of the selected tag to a virtual tag library generated using the nucleotide sequence of the genome or the part of a genome, the nucleotide sequence of the full recognition sequence of the MMRE, the nucleotide sequence of the full recognition sequence of the FRE, and the number of nucleotides separating the full recognition sequence of the RRE from the RRE cutting site."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A method of determining the chromosomal location of a plurality of unmethylated recognition sequences of the MMRE, the method comprising repeating the method of claim 14 with a plurality of tags obtained from the library."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the test cell is a vertebrate cell."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the test cell is a mammalian test cell."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the mammalian test cell is a human test cell."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the test cell is a normal cell."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the test cell is a cancer cell."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 21, wherein the cancer cell is a breast cancer cell."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the first member of the affinity pair is biotin or iminobiotin."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the first member of the affinity pair is an antigen, a haptenic determinant, a single-stranded nucleotide sequence, a hormone, a ligand for adhesion receptor, a receptor for an adhesion ligand, a ligand for a lectin, a lectin, a molecule containing all or part of an immunoglobulin Fc region, bacterial protein A, or bacterial protein G."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the insoluble substrate comprises magnetic beads."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["A method of classifying a biological cell, the method comprising:\n
(a) performing the method of claim 12, thereby obtaining a test MSDK profile for the test cell;\n
(b) comparing the test MSDK profile to separate control MSDK expression profiles for one or more control cell types;\n
(c) selecting a control MSDK profile that most closely resembles the test MSKD profile; and\n
(d) assigning to the test cell a cell type that matches the cell type of the control MSDK profile selected in step (c)."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the test and control cells are vertebrate cells."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 27, wherein the test and control cells are mammalian cells."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the test and control cells are human cells."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the control cell types comprise a control normal cell and a control cancer cell of the same tissue as the normal cell."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 30, wherein the control normal cell and the control cancer cell are breast cells."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 30, wherein the control normal cell and the control cancer cell are of a tissue selected from the group consisting of colon, lung, prostate, and pancreas."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 30, wherein the test cell is a breast cell."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 30, wherein the test cell is of a tissue selected from the group consisting of colon, lung, prostate, and pancreas."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the control cell types comprise cells of different categories of a cancer of a single tissue."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 35, wherein the different categories of a cancer of a single tissue comprise a breast ductal carcinoma in situ (DCIS) cell and an invasive breast cancer cell."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 35, wherein the different categories of a cancer of a single tissue comprise two or more of: a high grade DCIS cell, an intermediate grade DCIS cell; and an low grade DCIS cell."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the control cell types comprise two or more of: a lung cancer cell; a breast cancer cell; a colon cancer cell; a prostate cancer cell; and a pancreatic cancer cell."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the control cell types comprise an epithelial cell obtained from non-cancerous tissue and a myoepithelial cell obtained from non-cancerous tissue."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis, the method comprising:\n
(a) providing a test breast epithelial cell;\n
(b) determining the degree of methylation of one or more C residues in a gene in the test cell, wherein the gene is selected from those identified by the MSDK tags listed in Table 5, wherein the one or more C residues are C residues in CpG sequences; and\n
(c) comparing the degree of methylation of the one or more residues to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control epithelial cell obtained from non-cancerous breast tissue, wherein an altered degree of methylation of the one or more C residues in the test epithelial cell compared to the control epithelial cell is an indication that the test epithelial cell is a cancer cell."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["41-44. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein the gene is selected from the group consisting of PRDM14 and ZCCHC14."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis, the method comprising:\n
(a) providing a test colon epithelial cell;\n
(b) determining the degree of methylation of one or more C residues in a gene in the test cell, wherein the gene is selected from those identified by the MSDK tags listed in Table 2, wherein the one or more C residues are C residues in CpG sequences; and\n
(c) comparing the degree of methylation of the one or more residues to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control epithelial cell obtained from non-cancerous colon tissue, wherein an altered degree of methylation of the one or more C residues in the test epithelial cell compared to the control epithelial cell is an indication that the test epithelial cell is a cancer cell."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["47-50. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 46, wherein the gene is selected from the group consisting of LHX3, TCF7L1, and LMX-1A."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis, the method comprising:\n
(a) providing a test myoepithelial cell obtained from a test breast tissue;\n
(b) determining the degree of methylation of one or more C residues in a gene in the test cell, wherein the gene is selected from those identified by the MSDK tags listed in Table 10, wherein the one or more C residues are C residues in CpG sequences; and\n
(c) comparing the degree of methylation of the one or more residues to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control myoepithelial cell obtained from non-cancerous breast tissue, wherein an altered degree of methylation of the one or more C residues in the test myoepithelial cell compared to the control myoepithelial cell is an indication that the test breast tissue is cancerous tissue."],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["53-56. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 52, wherein the gene is selected from the group consisting of HOXD4, SLC9A3R1, and CDC42EP5."],"number":57,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis, the method comprising:\n
(a) providing a test fibroblast obtained from a test breast tissue;\n
(b) determining the degree of methylation of one or more C residues in a gene in the test cell, wherein the gene is selected from those identified by the MSDK tags listed in Tables 7 and 8, wherein the one or more C residues are C residues in CpG sequences; and\n
(c) comparing the degree of methylation of the one or more residues to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control fibroblast obtained from non-cancerous breast tissue, wherein an altered degree of methylation of the one or more C residues in the test fibroblast compared to the control fibroblast is an indication that the test breast tissue is cancerous tissue."],"number":58,"annotation":false,"claim":true,"title":false},{"lines":["59-62. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 58 wherein the gene is Cxorf12."],"number":63,"annotation":false,"claim":true,"title":false},{"lines":["A method of determining the likelihood of a cell being an epithelial cell or a myoepithelial cell, the method comprising:\n
(a) providing a test cell;\n
(b) determining the degree of methylation of one or more C residues in a gene in the test cell, wherein the gene is selected from those identified by the MSDK tags listed in Table 12, wherein the one or more C residues are C residues in CpG sequences; and\n
(c) comparing the degree of methylation of the one or more residues to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control myoepithelial cell and to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control epithelial cell, wherein the test cell is: (i) more likely to be a myoepithelial cell if the degree of methylation in the test sample more closely resembles the degree of methylation in the control myoepithelial cell; or (ii) more likely to be an epithelial cell if the degree of methylation in the test sample more closely resembles the degree of methylation in the control epithelial cell."],"number":64,"annotation":false,"claim":true,"title":false},{"lines":["65-66. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 64, wherein the gene is selected from the group consisting of LOC389333 and CDC42EP5."],"number":67,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis, the method comprising:\n
(a) providing a test cell from a test tissue;\n
(b) determining the degree of methylation of one or more C residues in a PRDM14 gene in the test cell, wherein the one or more C residues are C residues in CpG sequences; and\n
(c) comparing the degree of methylation of the one or more residues to the degree of methylation of corresponding one or more C residues in the PRDM14 gene in a control cell obtained from non-cancerous tissue of the same tissue as the test cell, wherein an altered degree of methylation of the one or more C residues in the test cell compared to the control cell is an indication that the test cell is a cancer cell."],"number":68,"annotation":false,"claim":true,"title":false},{"lines":["69-74. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis comprising:\n
(a) providing a test sample of breast tissue comprising a test epithelial cell;\n
(b) determining the level of expression in the test epithelial cell of a gene selected from those listed in Table 5, wherein the gene is one that is expressed in a breast cancer epithelial cell at a substantially altered level compared to a compared to a normal breast epithelial cell; and\n
(c) classifying the test cell as: (i) a normal breast epithelial cell if the level of expression of the gene in the test cell is not substantially altered compared to a control level of expression for a normal breast epithelial cell; or (ii) a breast cancer epithelial cell if the level of expression of the gene in the test cell is substantially altered compared to a control level of expression for a normal breast epithelial cell."],"number":75,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 75, wherein the gene is selected from the group consisting of PRDM14 and ZCCHC14."],"number":76,"annotation":false,"claim":true,"title":false},{"lines":["77-78. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis comprising:\n
(a) providing a test sample of colon tissue comprising a test epithelial cell;\n
(b) determining the level of expression in the test epithelial cell of a gene selected from those listed in Table 2, wherein the gene is one that is expressed in a colon cancer epithelial cell at a substantially altered level compared to a compared to a normal colon epithelial cell; and\n
(c) classifying the test cell as: (i) a normal colon epithelial cell if the level of expression of the gene in the test cell is not substantially altered compared to a control level of expression for a normal colon epithelial cell; or (ii) a colon cancer epithelial cell if the level of expression of the gene in the test cell is substantially altered compared to a control level of expression for a normal colon epithelial cell."],"number":79,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 79, wherein the gene is selected from the group consisting of LHX3, TCF7L1, and LMX-1A."],"number":80,"annotation":false,"claim":true,"title":false},{"lines":["81-82. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis comprising:\n
(a) providing a test sample of breast tissue comprising a test stromal cell;\n
(b) determining the level of expression in the stromal cell of a gene selected from those listed in Tables 7, 8, and 10, wherein the gene is one that is expressed in a cell of the same type as the test stromal cell at a substantially altered level when present in breast cancer tissue than when present in normal breast tissue; and\n
(c) classifying the test sample as: (i) normal breast tissue if the level of expression of the gene in the test stromal cell is not substantially altered compared to a control level of expression for a control cell of the same type as the test stromal cell in normal breast tissue; or (ii) breast cancer tissue if the level of expression of the gene in the test stromal cell is substantially altered compared to a control level of expression for a control cell of the same type as the test stromal cell in normal breast tissue."],"number":83,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":84,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 83, wherein the gene is selected from the group consisting of HOXD4, SLC9A3R1, and CDC32EP5."],"number":85,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":86,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 83, wherein the gene is Cxorf12."],"number":87,"annotation":false,"claim":true,"title":false},{"lines":["88-89. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["A method of determining the likelihood of a cell being an epithelial cell or a myoepithelial cell, the method comprising:\n
(a) providing a test cell;\n
(b) determining the level of expression in the test sample of a gene selected from the group consisting of those identified by the MSDK tags listed in Table 12;\n
(c) determining whether the level of expression of the selected gene in the test sample more closely resembles the level of expression of the selected gene in (i) a control myoepithelial cell or (ii) a control epithelial cell; and\n
(d) classifying the test cell as: (i) likely to be a myoepithelial cell if the level of expression of the gene in the test cell more closely resembles the level of expression of the gene in a control myoepithelial cell; or (ii) likely to be an epithelial cell if the level of expression of the gene in the test cell more closely resembles the level of expression of the gene in a control epithelial cell."],"number":90,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 90, wherein the gene is selected from the group consisting of LOC389333 and CDC42EP5."],"number":91,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosis comprising:\n
(a) providing a test cell;\n
(b) determining the level of expression in the test cell of a PRDM14 gene; and\n
(c) classifying the test cell as: (i) a normal cell if the level of expression of the gene in the test cell is not substantially altered compared to a control level of expression for a control normal cell of the same tissue as the test cell; or (ii) a cancer cell if the level of expression of the gene in the test cell is substantially altered compared to a control level of expression for a control normal cell of the same tissue as the test cell."],"number":92,"annotation":false,"claim":true,"title":false},{"lines":["93-96. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["A single stranded nucleic acid probe comprising:\n
(a) the nucleotide sequence of a tag selected from those listed in Tables 2, 5, 7, 8, 10, 12, 15, and 16; or\n
(b) the complement of the nucleotide sequence."],"number":97,"annotation":false,"claim":true,"title":false},{"lines":["An array comprising a substrate having at least 10 addresses, wherein each address has disposed thereon a capture probe comprising:\n
(a) a nucleic acid sequence consisting of a tag nucleotide sequence selected from those listed in Tables 2, 5, 7, 8, 10, 12, 15 and 16; or\n
(b) the complement of the nucleic acid sequence."],"number":98,"annotation":false,"claim":true,"title":false},{"lines":["A kit comprising at least 10 probes, each probe comprising:\n
(a) a nucleic acid sequence comprising a tag nucleotide sequence selected from those listed in Tables 2, 5, 7, 8, 10, 12, 15 and 16; or\n
(b) the complement of the nucleic acid sequence."],"number":99,"annotation":false,"claim":true,"title":false},{"lines":["A kit comprising at least 10 antibodies each of which is specific for a different protein encoded by a gene identified by a tag selected from the group consisting of the tags listed in Tables 2, 5, 7, 8, 10, 12, 15, and 16."],"number":100,"annotation":false,"claim":true,"title":false},{"lines":["A method of determining the likelihood of a cell being a stem cell, an differentiated luminal epithelial cell or a myoepithelial cell, the method comprising:\n
(a) providing a test cell;\n
(b) determining the degree of methylation of one or more C residues in a gene in the test cell, wherein the gene is selected from those identified by the MSDK tags listed in Table 15 or 16, wherein the one or more C residues are C residues in CpG sequences; and\n
(c) comparing the degree of methylation of the one or more residues to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control stem cell, to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control stem cell, and to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control differentiated luminal epithelial cell, and to the degree of methylation of corresponding one or more C residues in a corresponding gene in a control myoepithelial cell, wherein the test cell is: (i) more likely to be a stem cell if the degree of methylation in the test cell more closely resembles the degree of methylation in the control stem cell; (ii) more likely to be a differentiated luminal epithelial cell if the degree of methylation in the test cell more closely resembles the degree of methylation in the control differentiated luminal epithelial cell; or (iii) more likely to be an myoepithelial cell if the degree of methylation in the test cell more closely resembles the degree of methylation in the control myoepithelial cell"],"number":101,"annotation":false,"claim":true,"title":false},{"lines":["102-103. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 101, wherein the gene is selected from the group consisting of SOX13, SLC9A3R1, FNDC1, FOXC1, PACAP, DDN, CDC42EP5, LHX1, and HOXA10."],"number":104,"annotation":false,"claim":true,"title":false},{"lines":["A method of determining the likelihood of a cell being a stem cell, a differentiated luminal epithelial cell, or a myoepithelial cell, the method comprising:\n
(a) providing a test cell;\n
(b) determining the level of expression in the test sample of a gene selected from the group consisting of those identified by the MSDK tags listed in Table 15 or 16;\n
(c) determining whether the level of expression of the selected gene in the test sample more closely resembles the level of expression of the selected gene in (i) a control stem cell, (ii) a control differentiated luminal epithelial cell, or (ii) a control myoepithelial cell; and\n
(d) classifying the test cell as: (i) likely to be a stem cell if the level of expression of the gene in the test cell more closely resembles the level of expression of the gene in a control stem cell; (ii) likely to be a differentiated luminal epithelial cell if the level of expression of the gene in the test cell more closely resembles the level of expression of the gene in a control epithelial cell; or (iii) likely to be an myoepithelial cell if the level of expression of the gene in the test cell more closely resembles the level of expression of the gene in a control myoepithelial cell."],"number":105,"annotation":false,"claim":true,"title":false},{"lines":["106-107. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 105, wherein the gene is selected from the group consisting of SOX13, SLC9A3R1, FNDC1, FOXC1, PACAP, DDN, CDC42EP5, LHX1, and HOXA10."],"number":108,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}